Learning Objectives
Upon completion of this activity, participants should be able to:
- Define immune thrombocytopenia as part of the spectrum of thrombocytopenic disorders
- Review existing guidelines for the diagnosis of immune thrombocytopenia
- Describe current standard treatments for immune thrombocytopenia
- Evaluate new information on recently approved thrombopoietic agents
- Discuss experimental agents and future directions in the management of immune thrombocytopenia
Topics covered include:
- Immune Thrombocytopenia in the Spectrum of Thrombocytopenic Conditions
- Pathophysiology of Primary ITP
- Diagnosis of Primary ITP
- Indications for Treatment—Who to Treat, When to Treat
- Traditional Approaches to Treating Primary ITP: Corticosteroids and Splenectomy
- Traditional Approaches to Treating Primary ITP: IVIg and Anti-D
- Traditional Approaches to Treating Primary ITP: Rituximab
- Newer Treatment Approaches for Primary ITP
- Future Therapy for Primary ITP
- Summary and the Author’s Conclusions and Recommendations
Abstract